Skip to content

IAS: Randomised comparison concludes d4T more tolerable than AZT in triple nuke PEP regimen

Sustainability of antiretroviral therapy in HIV-infected adult urban Kenyans: lessons for other resource-poor countries

Frequent switchers have lower quality of life, higher suicidality

Four-year analysis of tenofovir finds “favourable safety profile”

WHO issues clarification on pharmacovigilance funding

Roche agrees to temporary suspension of nelfinavir's (Viracept) European license - updated

World Health Organization to monitor ARV side-effects worldwide

Link between diabetes and antiretrovirals may particularly affect resource-poor settings

Abacavir hypersensitivity screen as part of drug resistance test possible